Autolus Therapeutics plcAutolus Therapeutics plcAutolus Therapeutics plc

Autolus Therapeutics plc

No trades
See on Supercharts
Market capitalization
‪835.69 M‬USD
−1.20USD
‪−208.38 M‬USD
‪1.70 M‬USD
‪157.78 M‬
Beta (1Y)
3.89

About Autolus Therapeutics plc

CEO
Christian Martin Itin
Headquarters
London
Employees (FY)
463
Founded
2018
ISIN
US05280R1005
FIGI
BBG00KVT05R6
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.